- Home
- PYXS vs CLLS Comparison
PYXS vs CLLS Comparison
Compare PYXS & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYXS
- CLLS
- Stock Information
- Founded
- PYXS 2018
- CLLS 1999
- Country
- PYXS United States
- CLLS France
- Employees
- PYXS N/A
- CLLS N/A
- Industry
- PYXS Biotechnology: Pharmaceutical Preparations
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- PYXS Health Care
- CLLS Health Care
- Exchange
- PYXS Nasdaq
- CLLS Nasdaq
- Market Cap
- PYXS 210.4M
- CLLS 240.2M
- IPO Year
- PYXS 2021
- CLLS 2007
- Fundamental
- Price
- PYXS $3.23
- CLLS $1.91
- Analyst Decision
- PYXS Strong Buy
- CLLS Buy
- Analyst Count
- PYXS 6
- CLLS 2
- Target Price
- PYXS $9.00
- CLLS $8.00
- AVG Volume (30 Days)
- PYXS 456.9K
- CLLS 25.4K
- Earning Date
- PYXS 11-05-2024
- CLLS 11-04-2024
- Dividend Yield
- PYXS N/A
- CLLS N/A
- EPS Growth
- PYXS N/A
- CLLS N/A
- EPS
- PYXS N/A
- CLLS N/A
- Revenue
- PYXS $16,146,000.00
- CLLS $19,635,000.00
- Revenue This Year
- PYXS N/A
- CLLS $271.02
- Revenue Next Year
- PYXS N/A
- CLLS $33.48
- P/E Ratio
- PYXS N/A
- CLLS N/A
- Revenue Growth
- PYXS N/A
- CLLS N/A
- 52 Week Low
- PYXS $1.35
- CLLS $0.96
- 52 Week High
- PYXS $6.85
- CLLS $3.77
- Technical
- Relative Strength Index (RSI)
- PYXS 40.94
- CLLS 36.61
- Support Level
- PYXS $3.11
- CLLS $1.95
- Resistance Level
- PYXS $3.42
- CLLS $2.06
- Average True Range (ATR)
- PYXS 0.16
- CLLS 0.10
- MACD
- PYXS -0.02
- CLLS -0.01
- Stochastic Oscillator
- PYXS 32.86
- CLLS 9.37
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.